Actively Recruiting
Evaluating Recombinant Human Plasma Gelsolin With Standard Care for Moderate-to-Severe ARDS Caused by Pneumonia or Infections in a Randomized Placebo-Controlled Study
Led by BioAegis Therapeutics Inc. · Updated on 2026-10-20
600
Participants Needed
65
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of recombinant human plasma gelsolin rhu-pGSN combined with standard care in adults with moderate-to-severe Acute Respiratory Distress Syndrome ARDS caused by pneumonia or other infections. This Phase 2, randomized, double-blind, placebo-controlled study aims to enroll patients hospitalized within 24 hours of ARDS diagnosis, focusing on those with a low oxygenation ratio PF ratio 4150 requiring mechanical or noninvasive ventilation or high-flow oxygen support. Participants are randomly assigned to receive either rhu-pGSN or a matching saline placebo alongside standard care. The treatment involves a single loading dose of rhu-pGSN at 24 mgkg, followed by five daily doses of 12 mgkg administered intravenously through a filtered syringe. Patients receive the study drug within 48 hours of ARDS diagnosis. The study includes assessments such as blood tests, imaging, cultures, and antibody measurements at baseline and specified times. Safety reviews are conducted periodically by an independent monitoring board. Throughout the study, participants undergo detailed evaluations including medical history, infection site identification, physical exams, chest imaging, blood and sputum cultures, and laboratory tests for inflammatory markers. Follow-up occurs on Days 7, 14, 28, and 60 to assess mortality and respiratory support outcomes. Safety monitoring includes serious adverse event reviews. The total participation duration extends through at least 60 days following treatment to evaluate all-cause mortality and other clinical outcomes.
CONDITIONS
Brief Title
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
Research Team
H
Howard Levy, MD PhD
D
Dmytro Pomishchyk
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here